BeiGene, Ltd.
BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatm… Read more
BeiGene, Ltd. (ONC) - Total Liabilities
Latest total liabilities as of December 2025: $3.83 Billion USD
Based on the latest financial reports, BeiGene, Ltd. (ONC) has total liabilities worth $3.83 Billion USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
BeiGene, Ltd. - Total Liabilities Trend (2013–2025)
This chart illustrates how BeiGene, Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
BeiGene, Ltd. Competitors by Total Liabilities
The table below lists competitors of BeiGene, Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chunghwa Telecom Co Ltd
NYSE:CHT
|
USA | $135.42 Billion |
|
Keurig Dr Pepper Inc
NASDAQ:KDP
|
USA | $29.94 Billion |
|
Archer-Daniels-Midland Company
NYSE:ADM
|
USA | $11.63 Billion |
|
Engie SA
PINK:ENGQF
|
USA | $126.41 Billion |
|
Hyundai Motor S3 Pref
KO:005389
|
Korea | ₩229.09 Trillion |
|
Ingersoll Rand Inc
NYSE:IR
|
USA | $8.00 Billion |
|
Volvo AB Series A
LSE:0MHW
|
UK | Skr374.81 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down BeiGene, Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BeiGene, Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BeiGene, Ltd. (2013–2025)
The table below shows the annual total liabilities of BeiGene, Ltd. from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $3.83 Billion | +47.85% |
| 2024-12-31 | $2.59 Billion | +14.14% |
| 2023-12-31 | $2.27 Billion | +13.63% |
| 2022-12-31 | $2.00 Billion | -16.94% |
| 2021-12-31 | $2.40 Billion | +38.78% |
| 2020-12-31 | $1.73 Billion | +173.14% |
| 2019-12-31 | $633.93 Million | +27.80% |
| 2018-12-31 | $496.04 Million | +36.93% |
| 2017-12-31 | $362.25 Million | +584.70% |
| 2016-12-31 | $52.91 Million | +24.65% |
| 2015-12-31 | $42.45 Million | +52.39% |
| 2014-12-31 | $27.85 Million | -42.87% |
| 2013-12-31 | $48.76 Million | -- |